We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 1-10 of 799

Health Hacking: Dealing with the cyber threat in digital health
  • Corrs Chambers Westgarth
  • Australia
  • September 1 2017

Software and the electronic devices it controls, has become increasingly important in the healthcare industry over recent years. Digital health

The Past, Present, and Future of Government Regulation of Off-Label Communications - Part 4
  • Mintz Levin
  • USA
  • August 14 2017

Picking up from my last installment of this series exploring the regulatory history of off-label communication, this post highlights some recent

Washington Healthcare Update - June 12, 2017
  • McGuireWoods LLP
  • USA
  • June 12 2017

On June 7, the House Energy and Commerce Committee reported out a bill reauthorizing FDA user fee programs for drugs and medical devices in a

White House Fiscal Year 2018 "Skinny Budget" Targets Discretionary Healthcare Spending
  • Sidley Austin LLP
  • USA
  • March 29 2017

On March 16, U.S. President Donald Trump released his fiscal year (FY) 2018 budget blueprint, known colloquially as the "Skinny Budget." The release

Continued Coverage of the SXSW Interactive Conference, Health Track - Accuracy: Consumer Wearables and Academic Research
  • Husch Blackwell LLP
  • USA
  • March 13 2017

Given the transformations taking place at every level in healthcare, it is no surprise that the 2017 SXSW Interactive Conference has a big spotlight

FDA Hits “Pause” on Regulation of LDTs
  • Foley & Lardner LLP
  • USA
  • February 12 2017

On January 13, 2017, the U.S. Food and Drug Administration (FDA) issued a Discussion Paper on Laboratory Developed Tests (LDTs) (LDTs) (Discussion

Rand Corporation Issues Report on U.S. Blood System
  • Foley & Lardner LLP
  • USA
  • February 6 2017

“A robust, sustainable blood system is a crucial component of every health care system.” That is how Rand Corporation’s recently issued comprehensive

Rep. Tom Price Confirmation Hearings - What we have learned
  • Husch Blackwell LLP
  • USA
  • January 30 2017

President Trump's nominee for Secretary of the Department of Health & Human Services (HHS), Congressman Tom Price (R-Ga.), has now completed two

Radiopharmacies Celebrate the New Year with Long-Awaited FDA Guidance
  • Reed Smith LLP
  • USA
  • December 31 2016

On December 29, 2016, the U.S. Food and Drug Administration (“FDA”) surprised many in the radiopharmacy industry by issuing a long-awaited draft

Health Law Update - December 15, 2016
  • Baker & Hostetler LLP
  • USA
  • December 15 2016

Welcome to this week's edition of the Health Law Update. In this Issue: 21st Century Cures: Not Just a Biomed Bill 21st Century Cures: Ambitious